Cargando…

Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?

SIMPLE SUMMARY: Current cancer testing gene panels tend to be comprehensive. One of the genes commonly included in the testing panels is BARD1. To establish whether BARD1 mutations predispose to prostate cancer, we sequenced BARD1 in 390 hereditary prostate cancer cases, genotyped 5715 men with unse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stempa, Klaudia, Wokołorczyk, Dominika, Kluźniak, Wojciech, Rogoża-Janiszewska, Emilia, Malińska, Karolina, Rudnicka, Helena, Huzarski, Tomasz, Gronwald, Jacek, Gliniewicz, Katarzyna, Dębniak, Tadeusz, Jakubowska, Anna, Lener, Marcin, Tomiczek-Szwiec, Joanna, Domagała, Paweł, Suszynska, Malwina, Kozlowski, Piotr, Kluz, Tomasz, Naczk, Mariusz, Lubiński, Jan, Narod, Steven A., Akbari, Mohammad R., Cybulski, Cezary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582358/ https://www.ncbi.nlm.nih.gov/pubmed/34771627 http://dx.doi.org/10.3390/cancers13215464

Ejemplares similares

The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
por: Gliniewicz, Katarzyna, et al.
Publicado: (2023)

BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation
por: Suszynska, Malwina, et al.
Publicado: (2019)

Inherited variants in XRCC2 and the risk of breast cancer
por: Kluźniak, Wojciech, et al.
Publicado: (2019)

Genetic predisposition to male breast cancer in Poland
por: Szwiec, Marek, et al.
Publicado: (2021)

Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer
por: Kluźniak, Wojciech, et al.
Publicado: (2019)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

Serum Selenium Level and 10-Year Survival after Melanoma
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2021)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Risk of Second Primary Thyroid Cancer in Women with Breast Cancer
por: Cieszyńska, Monika, et al.
Publicado: (2022)

Inherited NBN Mutations and Prostate Cancer Risk and Survival
por: Rusak, Bogna, et al.
Publicado: (2019)

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer
por: Szwiec, Marek, et al.
Publicado: (2021)

BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population
por: Dębniak, Tadeusz, et al.
Publicado: (2018)

The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
por: Lener, Marcin R., et al.
Publicado: (2017)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2016: Szczecin, Poland. 14-15 September 2016
por: Cybulski, C., et al.
Publicado: (2017)

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
por: Gronwald, J, et al.
Publicado: (2009)

Serum Essential Elements and Survival after Cancer Diagnosis
por: Lubiński, Jan, et al.
Publicado: (2023)

Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations
por: Suszynska, Malwina, et al.
Publicado: (2020)

NBS1 Mutation and prognosis of prostate cancer
por: Wokołorczyk, Dominika, et al.
Publicado: (2012)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland
por: Baszuk, Piotr, et al.
Publicado: (2021)

Coverage of the Genetic Background of Breast Cancer in the Polish Population
por: Serrano-Fernández, Pablo, et al.
Publicado: (2006)

Serum selenium level and cancer risk: a nested case-control study
por: Narod, Steven A., et al.
Publicado: (2019)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Blood arsenic levels and the risk of familial breast cancer in Poland
por: Marciniak, Wojciech, et al.
Publicado: (2019)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs
por: Lubiński, Jan, et al.
Publicado: (2005)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland
por: Gronwald, Jacek, et al.
Publicado: (2006)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles
por: Cybulski, C, et al.
Publicado: (2013)

Founder Mutations for Early Onset Melanoma as Revealed by Whole Exome Sequencing Suggests That This is Not Associated with the Increasing Incidence of Melanoma in Poland
por: Dębniak, Tadeusz, et al.
Publicado: (2019)

Copper as diagnostic marker of cancers
por: Muszyńska, Magdalena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_li2s2euukr3du80uu0kbffgf3e